Literature DB >> 15316218

Bronchocentric granulomatosis associated with influenza-A virus infection.

J M van der Klooster1, L A C Nurmohamed, N A L van Kaam.   

Abstract

Bronchocentric granulomatosis is an unusual pathologic entity that is characterized by a necrotizing granulomatous inflammation surrounding the airways. The diagnosis is usually made retrospectively, after histopathologic examination of an open-lung biopsy or resection of a pulmonary lesion. Although the aetiology has not been fully elucidated, the current pathogenetic mechanism is considered to be an immunologic reaction against endobronchial antigens, since most patients exhibit signs of bronchial asthma, eosinophilia and allergic bronchopulmonary aspergillosis. However, non-asthmatic patients may develop bronchocentric granulomatosis without signs for endobronchial fungal infections, but probably as a consequence of other pulmonary infections. An 80-year-old female patient presented with high fever and bilateral pulmonary infiltrates and nodules. After extensive investigations and open-lung biopsy, the diagnosis bronchocentric granulomatosis was established that was possibly associated with an influenza-A virus infection. Treatment consisted of immunosuppressive drugs (prednisone and cyclophosphamide), which led to complete clinical and radiological recovery. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2004        PMID: 15316218     DOI: 10.1159/000079649

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  2 in total

1.  Bronchocentric granulomatosis in a patient with rheumatoid arthritis.

Authors:  Cemal Bes; Ali Kılıçgün; Fahrettin Talay; Fahri Yılmaz; Mehmet Soy
Journal:  Rheumatol Int       Date:  2010-04-09       Impact factor: 2.631

2.  Identification of a novel antigen-presenting cell population modulating antiinfluenza type 2 immunity.

Authors:  Jae-Kwang Yoo; Carole L Galligan; Carl Virtanen; Eleanor N Fish
Journal:  J Exp Med       Date:  2010-06-14       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.